Paraneoplastic Neurological Syndrome in a Patient with Limited-stage Small-cell Lung Cancer Receiving Durvalumab Maintenance after Concurrent Chemoradiotherapy: A Case Report
Abstract
Paraneoplastic neurological syndromes (PNSs) are immune-mediated disorders associated with small-cell lung cancer (SCLC). Durvalumab following concurrent chemoradiotherapy (cCRT) improves outcomes in patients with limited-stage SCLC (LS-SCLC); however, its safety in patients with pre-existing PNS and residual neurological deficits is uncertain. A 63-year-old woman with LS-SCLC and definite PNS (anti-Hu/anti-SOX1-positive subacute cerebellar syndrome, PNS-Care score 10) received cCRT followed by durvalumab maintenance therapy. No neurological worsening or severe immune-related adverse events occurred during approximately one year of durvalumab maintenance therapy, and the tumor response was sustained. Durvalumab maintenance after cCRT may be feasible in carefully selected patients with LS-SCLC and clinically stable pre-existing PNS and residual neurological deficits, under close multidisciplinary monitoring.
Related
- Durvalumab completion and re-administration after grade 2 radiation pneumonitis following concurrent chemoradiotherapy for unresectable stage III NSCLC: a single-center real-world study
- InDuRanS: neoadjuvant immunochemotherapy followed by surgery or definitive chemoradiotherapy and consolidation durvalumab in resectable and borderline resectable stage IIB-IIIA/B non-small-cell lung cancer.
- Anti-Ma1/Ma2 paraneoplastic neurological syndrome associated with malignant mesothelioma: a case study.
- Sequential chemoradiotherapy vs. radiotherapy alone or concurrent chemoradiotherapy after radical resection of stage IA2–IIA1 cervical cancer: a retrospective cohort study
- A Systematic Review and Meta-Analysis: Does Molecular Hydrogen Exert Radioprotective Effects Without Compromising the Antitumor Efficacy of Radiotherapy or Concurrent Chemoradiotherapy?
BibTeX
@article{abe2026paraneoplastic,
title = {{Paraneoplastic Neurological Syndrome in a Patient with Limited-stage Small-cell Lung Cancer Receiving Durvalumab Maintenance after Concurrent Chemoradiotherapy: A Case Report}},
author = {Daisuke Abe and Reiko Matsuzawa and Tomoki Hirunagi and Masahisa Katsuno and Yuta Mori and Shunsaku Hayai and Junji Koyama and Takayasu Ito and Kazumi Hori and Akira Ando and Ichidai Tanaka and Yuichiro Shindo and Koji Sakamoto and Makoto Ishii},
journal = {Internal Medicine},
year = {2026},
month = sep,
doi = {10.2169/internalmedicine.7992-26},
url = {https://www.jstage.jst.go.jp/article/internalmedicine/advpub/0/advpub_7992-26/_article},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Paraneoplastic Neurological Syndrome in a Patient with Limited-stage Small-cell Lung Cancer Receiving Durvalumab Maintenance after Concurrent Chemoradiotherapy: A Case Report
AU - Daisuke Abe
AU - Reiko Matsuzawa
AU - Tomoki Hirunagi
AU - Masahisa Katsuno
AU - Yuta Mori
AU - Shunsaku Hayai
AU - Junji Koyama
AU - Takayasu Ito
AU - Kazumi Hori
AU - Akira Ando
AU - Ichidai Tanaka
AU - Yuichiro Shindo
AU - Koji Sakamoto
AU - Makoto Ishii
PY - 2026
DA - 2026/09/15
JO - Internal Medicine
DO - 10.2169/internalmedicine.7992-26
UR - https://www.jstage.jst.go.jp/article/internalmedicine/advpub/0/advpub_7992-26/_article
AB - Paraneoplastic neurological syndromes (PNSs) are immune-mediated disorders associated with small-cell lung cancer (SCLC). Durvalumab following concurrent chemoradiotherapy (cCRT) improves outcomes in patients with limited-stage SCLC (LS-SCLC); however, its safety in patients with pre-existing PNS and residual neurological deficits is uncertain. A 63-year-old woman with LS-SCLC and definite PNS (anti-Hu/anti-SOX1-positive subacute cerebellar syndrome, PNS-Care score 10) received cCRT followed by durvalumab maintenance therapy. No neurological worsening or severe immune-related adverse events occurred during approximately one year of durvalumab maintenance therapy, and the tumor response was sustained. Durvalumab maintenance after cCRT may be feasible in carefully selected patients with LS-SCLC and clinically stable pre-existing PNS and residual neurological deficits, under close multidisciplinary monitoring.
SN - 1349-7235
SN - 0918-2918
ER -